Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC Chemotherapy and Epirubicin for Moderate-High Risk NMIBC
NCT02716961Unknown
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jan 2016
- Primary completion
- Dec 2020
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Open-label trial of gemcitabine and Cisplatin micelle injection (HA132) in Non-muscle-invasive bladder cancer (NMIBC) (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoints: Tumor progression at 5 years and Drug intervention complications at 2 years. Status: unknown.
02
Drugs
gemcitabineCisplatin micelle injection (HA132)
03
Conditions
Non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT02716961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02716961.